赫伯纳斯瓦克：慢性乙型肝炎背景下的研发与应用
HeberNasvac: Development and Application in the Context of Chronic Hepatitis B.
作者信息
Aguilar Julio C, Akbar Sheikh Mf, Al-Mahtab Mamun, Khan Md Sakirul I, Guzman Carlos A, Fernandez Guillermo, Aguiar Jorge A, Michel Marie-Louise, Bourgine Maryline, Marrero Maria A, Trittel Stephanie, Ebensen Thomas, Riese Peggy, Le Grand Roger, Herate Cecile, Mauras Aurelie, Yoshida Osamu, Hiasa Yoichi, Penton Eduardo, Guillen Gerardo E
机构信息
Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Japan.
出版信息
Euroasian J Hepatogastroenterol. 2024 Jul-Dec;14(2):221-237. doi: 10.5005/jp-journals-10018-1457. Epub 2024 Dec 27.
UNLABELLED
The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac experience is revisited for addressing the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation.
HOW TO CITE THIS ARTICLE
Aguilar JC, Akbar SMF, Al-Mahtab M, HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian J Hepato-Gastroenterol 2024;14(2):221-237.
未标注
免疫系统在控制急性乙型肝炎感染以及慢性乙型肝炎（CHB）患者病情缓解过程中发挥着核心作用。鉴于2.21亿（75%）慢性乙型肝炎患者居住在低收入和中等收入国家，研发具有治疗特性的疫苗是一种合理且具有成本效益的方法，而非浪漫的努力。本综述系统分析了与慢性乙型肝炎治疗的安全性、有效性和效能相关的关键变量。重新审视了HeberNasvac的经验，以应对治疗性疫苗的挑战和潜力，以及目前在研发、注册和大规模实施方面的障碍。
如何引用本文
阿吉拉尔JC、阿克巴尔SMF、马赫塔布M，HeberNasvac：在慢性乙型肝炎背景下的研发与应用。《欧亚肝脏胃肠病学杂志》2024年；14（2）：221 - 237。
Zotero 插件